{"id":31009,"date":"2025-08-28T15:23:51","date_gmt":"2025-08-28T15:23:51","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/celaid-therapeutics-have-executed-a-collaborative-research-agreement-with-agc-on-expansion-and-functional-evaluation-of-ipsc-hspcs\/"},"modified":"2025-08-28T15:23:51","modified_gmt":"2025-08-28T15:23:51","slug":"celaid-therapeutics-have-executed-a-collaborative-research-agreement-with-agc-on-expansion-and-functional-evaluation-of-ipsc-hspcs","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=31009","title":{"rendered":"Celaid Therapeutics have executed a collaborative research agreement with AGC on Expansion and Functional Evaluation of iPSC-HSPCs"},"content":{"rendered":"

TOKYO<\/span><\/span>, Aug. 28, 2025<\/span><\/span> \/PRNewswire\/ — Celaid Therapeutics Inc. (“Celaid”) have executed a collaborative research agreement with AGC Inc. (“AGC”) to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid’s proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC’s iPSC technology to accelerate\u00a0robust and scalable expansion of iPSC-HSPCs.<\/p>\n

In this project, Celaid’s human HSC expansion technology will be applied to AGC’s iPSC-HSPCs. The functionality of the expanded cells will be evaluated through in vitro<\/i> experiments and in vivo<\/i> animal transplantation. Through this collaboration, the two companies aim to demonstrate a method for large-scale expansion of high-quality iPSC-HSPCs – addressing key manufacturing challenges in the development of iPSC-derived blood and immune cell therapies.<\/p>\n

“We are excited to partner with AGC to leverage and combine cutting-edge stem cell technologies to drive future breakthroughs,” stated Nobuyuki Arakawa<\/span>, President and CEO of Celaid. “This collaboration represents a significant step toward resolving the key challenges in the clinical manufacturing of iPSC-derived hematopoietic and immune cell therapy products.”<\/p>\n

About Celaid Therapeutics Inc.<\/b><\/p>\n

Celaid Therapeutics Inc. is a startup born out of the University of Tokyo<\/span> and University of Tsukuba<\/span> with proprietary technology for selective ex vivo<\/i> HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo<\/i> HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases.<\/p>\n

About AGC<\/b><\/p>\n

AGC Inc. is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive, and display glass, chemicals, ceramics, and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 56,000 people worldwide and generates annual sales of approximately 2.0 trillion Japanese yen<\/span> through business in about 30 countries.<\/p>\n

Contact Information
<\/u><\/b>Celaid Therapeutics Inc.
<\/b>Address\uff1aUTokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo, Bunkyo-ku, Tokyo<\/span> 113-8485, Japan<\/span>
TEL\uff1a+81-50-3612-7767\uff0fE-mail\uff1acontact@celaidtx.com<\/a>
URL\uff1ahttps:\/\/celaidtx.com\/en\/<\/a><\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

TOKYO<\/span><\/span>, Aug. 28, 2025<\/span><\/span> \/PRNewswire\/ — Celaid Therapeutics Inc. (“Celaid”) have executed a collaborative research agreement with AGC Inc. (“AGC”) to advance iPS cell-derived hematopoietic stem and progenitor cells (iPSC-HSPCs). The collaboration aims to combine Celaid’s proprietary platform of hematopoietic stem cell (HSC) expansion technology with AGC’s iPSC technology to accelerate\u00a0robust and scalable expansion of iPSC-HSPCs.<\/p>\n

In this project, Celaid’s human HSC expansion technology will be applied to AGC’s iPSC-HSPCs. The functionality of the expanded cells will be evaluated through in vitro<\/i> experiments and in vivo<\/i> animal transplantation. Through this collaboration, the two companies aim to demonstrate a method for large-scale expansion of high-quality iPSC-HSPCs – addressing key manufacturing challenges in the development of iPSC-derived blood and immune cell therapies.<\/p>\n

“We are excited to partner with AGC to leverage and combine cutting-edge stem cell technologies to drive future breakthroughs,” stated Nobuyuki Arakawa<\/span>, President and CEO of Celaid. “This collaboration represents a significant step toward resolving the key challenges in the clinical manufacturing of iPSC-derived hematopoietic and immune cell therapy products.”<\/p>\n

About Celaid Therapeutics Inc.<\/b><\/p>\n

Celaid Therapeutics Inc. is a startup born out of the University of Tokyo<\/span> and University of Tsukuba<\/span> with proprietary technology for selective ex vivo<\/i> HSC expansion. By safely and efficiently expanding human HSCs, Celaid aims to provide the next generation of cell and gene therapy products for cell therapy targeting hematologic disease, ex vivo<\/i> HSC gene therapy for genetic disorders, and angiogenesis for ischemic diseases.<\/p>\n

About AGC<\/b><\/p>\n

AGC Inc. is the parent company of the AGC Group, a world-leading glass solution provider and supplier of flat, automotive, and display glass, chemicals, ceramics, and other high-tech materials and components. Based on more than a century of technical innovation, the AGC Group has developed a wide range of cutting-edge products. The AGC Group employs some 56,000 people worldwide and generates annual sales of approximately 2.0 trillion Japanese yen<\/span> through business in about 30 countries.<\/p>\n

Contact Information
<\/u><\/b>Celaid Therapeutics Inc.
<\/b>Address\uff1aUTokyo Entrepreneur Lab., South Clinical Research Bldg., 7-3-1 Hongo, Bunkyo-ku, Tokyo<\/span> 113-8485, Japan<\/span>
TEL\uff1a+81-50-3612-7767\uff0fE-mail\uff1acontact@celaidtx.com<\/a>
URL\uff1ahttps:\/\/celaidtx.com\/en\/<\/a><\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-31009","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31009","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=31009"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/31009\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=31009"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=31009"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=31009"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}